UFF
SUPN icon

USA Financial Formulas’s Supernus Pharmaceuticals SUPN Stock Holding History

USA Financial Formulas’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,051
Closed -$50.2K – 471
2025
Q3 		$50.2K Buy
+1,051
New +$42.3K 0.01% 223
2023
Q4 		– Sell
-3,438
Closed -$94.8K – 527
2023
Q3 		$94.8K Hold
3,438
– – 0.14% 154
2023
Q2 		$103K Sell
3,438
-185
-5% -$6.47K 0.16% 109
2023
Q1 		$131K Buy
+3,623
New +$139K 0.21% 68
2022
Q3 		$193K Buy
+5,713
New +$186K 0.3% 54
2017
Q4 		– Sell
-7,708
Closed -$308K – 336
2017
Q3 		$308K Buy
+7,708
New +$334K 0.07% 216

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

USA Financial Formulas's SUPN Position: Q4 2025 in Review

USA Financial Formulas sold out of Supernus Pharmaceuticals (SUPN) in Q4 2025, closing a stake of 1,051 shares — an estimated $50.2K sold.

USA Financial Formulas first reported a position in SUPN in Q3 2017 and held it in 6 quarters. The position peaked at $308K in Q3 2017. 333 funds tracked by Wall St. Rank hold SUPN as of Q4 2025.

  • USA Financial Formulas reported no remaining Supernus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • USA Financial Formulas sold 1,051 Supernus Pharmaceuticals shares in Q4 2025, an estimated $50.2K.
  • USA Financial Formulas first reported a position in Supernus Pharmaceuticals in Q3 2017 and held it in 6 quarters.
  • USA Financial Formulas's Supernus Pharmaceuticals position peaked at $308K in Q3 2017.
  • 333 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2025.

Based on USA Financial Formulas's 13F filing for Q4 2025, filed 14 Jan 2026.